Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials

Emily R. Atkins, Yoichiro Hirakawa, Mohammad Abdul Salam, Mark Woodward, Mark Cooper, Pavel Hamet, Stephen Harrap, Kennedy Lees, Lisheng Liu, Giuseppe Mancia, Michel Marre, Vlado Perkovic, Neil Poulter, Bryan Williams, John Chalmers, Anthony Rodgers

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

OBJECTIVE:: To measure the placebo-controlled effects of combination therapy on hypotension, treatment discontinuation, and major renal outcomes, according to baseline blood pressure. METHODS:: We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation and perindopril protection against recurrent stroke study trials, including 14?684 participants allocated combination therapy or placebo. The mean age was 65 years, 61% were men, and 64% were receiving background blood pressure lowering (BPL) therapy. Participants were stratified into five subgroups by baseline SBP less than 120, 120–129, 130–139, 140–159, and at least 160?mmHg. Discontinuation of study treatment during the active run-in phase and postrandomization follow-up was assessed for hypotension/dizziness and other causes. Major renal outcomes (sustained doubling in creatinine or renal death) were also assessed. RESULTS:: Discontinuation during the 4–6-week active run-in phase due to hypotension/dizziness ranged from 3.6% in those with SBP less than 120?mmHg to 1.3% in those with SBP at least 160?mmHg. Median follow-up in the randomized phase was 5.6 years, and discontinuation for hypotension was higher with combination therapy compared with placebo in the less than 120?mmHg group (4.7 vs. 1.2%). However, for each subgroup with baseline SBP 120–129, 130–139, and 140–159?mmHg, the absolute excess of discontinuation due to hypotension with combination therapy was 0.7%. Total discontinuations were only increased in the less than 120?mmHg group (18.4 vs. 12.5%) and the 120–129-mmHg subgroup (17.6 vs. 14.2%). There were no clear differences across the SBP subgroups for the combined renal outcome (overall, 0.8 vs. 0.6%). CONCLUSION:: Compared with those with baseline SBP 140–159?mmHg, side effects of dual combination BPL are essentially the same for people with SBP 130–139?mmHg and only modestly increased among patients with SBP 120–129?mmHg. During long-term therapy, side effects sufficient to stop treatment that are treatment related (i.e. occur in excess of rates seen with placebo) occur at less than 0.5%/year in patients with baseline SBP 120–139?mmHg. These results have important implications in assessing the likely balance of benefits and side effects of BPL with combination therapy among those with SBP 120–139?mmHg.

Original languageEnglish
Pages (from-to)1318 - 1325
Number of pages8
JournalJournal of Hypertension
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 2017
Externally publishedYes

Cite this